智通财经APP获悉，微创机器人-B(02252)涨超7%，截至发稿，涨6.85%，报9.83港元，成交额1.21亿港元。
消息面上，国务院加大对药品医疗器械研发创新的支持力度，提高药品医疗器械审评审批质效，审评审批资源更多向临床急需的重点创新药和医疗器械倾斜。中金研报指出，尽管受医疗行业整顿持续、设备招采进展缓慢、IVD和高耗集采等因素的影响，医疗器械上市公司近几个季度有一定业绩扰动，但我们也观察到这些因素的边际影响在逐步减弱或修复改善，2025年医疗器械板块细分赛道或有望受益于产品升级与海外出口。
微创机器人此前完成新一轮配售，收取所得款项净额约2.66亿港元。西南证券此前指，公司强化腔镜和骨科机器人的业务聚焦，国内海外双点开花。2024上半年公司净亏损2800万元，同比缩窄48.6%，自由现金流净流出2.4亿元（-49.7%），主要因公司自2023年实施降本增效和业务聚焦发展战略，实施高效的现金流管控措施、优化产品成本和集中资源倾斜图迈、腔镜等核心业务的优化和商业化销售，有利于公司中长期健康稳健发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.